Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Budesonide decreased the frequency of soft or watery stools and improved the patients' quality of life significantly in MCi, but the primary endpoint was not met due to the low sample size (type 2 error).
Most TEAEs were mild or moderate in severity and no patients discontinued from the OLE or required dose reductions due to TEAEs.
Considering, capital investment and maintenance, instrumentation and LOS, robotic cases were €651 more expensive per case.
IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma.
These results suggest that patients with knee wear-and-tear joint pain who respond well to duloxetine in the first month might experience sustained, long-term pain relief with generally greater quality-of-life improvement than.
There was no observed significant difference between chemoRT then chemo compared to sandwich therapy in terms of RFS, OS, or side effects, although the trial was underpowered and closed early due to low accrual.
Consistent with adult phase 3 trials, dasiglucagon rapidly and effectively restored PG levels following insulin-induced low blood sugar in children and adolescents with T1DM, with an overall safety profile similar to glucagon.
Although this phase III trial was underpowered, there was no evidence that SRT yielded outcome detriments compared to WBRT for EGFRm NSCLC BMs.
Late follicular phase stimulation is as efficient as early follicular phase stimulation in terms of the number of oocytes.
Trichiura and hookworm infections.Trial registration: ClinicalTrials.gov, NCT03527732.
In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed.
Convalescent plasma showed no significant clinical impact but may influence SARS-CoV-2 complexity.
In C5i-experienced patients, increased Hb levels correlated with improvement in FACIT-Fatigue scores (R = 0.48); in C5i-naive patients, increased Hb (R = 0.42) and decreased LDH (R = -0.53) (all P < .001) correlated with...
No AC-related side effects were reported.
The ORR was similar in both the arms; however, the CR rate was significantly higher in the BR arm.
No grade >3 toxicity was recorded.
Both doses of once-daily filgotinib 200 mg and filgotinib 100 mg were effective, and generally well-tolerated in Japanese patients with active refractory RA.
A significant decrease in UACR following dotinurad administration was observed.
Nab-paclitaxel-based regimen could be a safe and effective option as second- or later-line treatment in patients with advanced ESCC, regardless of their previous exposure to PD-1 inhibitors.
There were no significant differences between groups seen in either of the coprimary endpoints; furthermore, we found no association between whole blood everolimus trough concentrations and toxicity.
128 patients (placebo, n = 39; perampanel, n = 89) were included in the gold-standard blind Safety Analysis Set and 126 (FS, n = 113 [placebo, n = 32; perampanel, n = 81]; FBTCS, n = 35 [placebo, n = 14; perampanel, n = 21];...
Improvements with dupilumab vs.
The side effects were similar to those seen in patients with other types of kidney cancer treated with atezolizumab in the same study (IMmotion010).
MMT sum scores improved with IVIg compared with placebo after 8 weeks of dosing and two courses of treatment, but the differences were not statistically significant, and the results showed no clear efficacy of IVIg in this...
In MEfCRVO/MEfBRVO, a longer time to IAI treatment initiation was followed by less visual improvement.
Our results support the use of a self-reported pain outcome in predicting long-term pain-relieving following acupuncture in fibromyalgia.
The entire study population experienced long-term survival, with median OS well over five years.
Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.
A total of 68 HCWs met the eligibility criteria were randomly allocated to receive HCQ (n = 36) or not (n = 32).
Atezolizumab added to neoadjuvant chemotherapy numerically improved pathological complete response versus placebo in this small exploratory analysis of Japanese patients with early stage triple-negative breast cancer, a trend...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
